Treatment of paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated nephropathies, and age-related macular degeneration (AMD)
Target
C3 (C3b) [HSA:718] [KO:K03990]
Pathway
hsa04610
Complement and coagulation cascades
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA54 Pegcetacoplan
D11613 Pegcetacoplan (JAN/USAN/INN)
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Complement Inhibitors
Pegcetacoplan
D11613 Pegcetacoplan (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Organismal systems
Complement and coagulation
C3 (C3b)
D11613 Pegcetacoplan (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11613
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11613
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11613